NYXH Stock Overview
A medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea (OSA). More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Nyxoah S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €5.54 |
| 52 Week High | €11.40 |
| 52 Week Low | €5.04 |
| Beta | 0.65 |
| 1 Month Change | -47.24% |
| 3 Month Change | -46.73% |
| 1 Year Change | -39.78% |
| 3 Year Change | -66.42% |
| 5 Year Change | n/a |
| Change since IPO | -71.59% |
Recent News & Updates
Recent updates
FDA Approval Will Launch Genio And Expand Global Reach
Apr 06 Imminent FDA approval of Genio could significantly boost revenues and market penetration in the U.S., driven by robust clinical results and strategic recruitment.It's Probably Less Likely That Nyxoah S.A.'s (EBR:NYXH) CEO Will See A Huge Pay Rise This Year
Jun 05
Rock star Growth Puts Nyxoah (EBR:NYXH) In A Position To Use Debt
Jan 24Do Insiders Own Lots Of Shares In Nyxoah S.A. (EBR:NYXH)?
Dec 21Shareholder Returns
| NYXH | BE Medical Equipment | BE Market | |
|---|---|---|---|
| 7D | -1.9% | 2.5% | 5.0% |
| 1Y | -39.8% | -1.8% | 3.0% |
Return vs Industry: NYXH underperformed the Belgian Medical Equipment industry which returned -1.8% over the past year.
Return vs Market: NYXH underperformed the Belgian Market which returned 3% over the past year.
Price Volatility
| NYXH volatility | |
|---|---|
| NYXH Average Weekly Movement | 10.8% |
| Medical Equipment Industry Average Movement | 6.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in BE Market | 8.4% |
| 10% least volatile stocks in BE Market | 2.6% |
Stable Share Price: NYXH's share price has been volatile over the past 3 months compared to the Belgian market.
Volatility Over Time: NYXH's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Belgian stocks.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 184 | Olivier Taelman | www.nyxoah.com |
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea (OSA). Its lead solution, Genio system, is a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy for the treatment of moderate to severe OSA. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Nyxoah S.A. Fundamentals Summary
| NYXH fundamental statistics | |
|---|---|
| Market cap | €207.35m |
| Earnings (TTM) | -€59.24m |
| Revenue (TTM) | €4.52m |
45.9x
P/S Ratio-3.5x
P/E RatioIs NYXH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NYXH income statement (TTM) | |
|---|---|
| Revenue | €4.52m |
| Cost of Revenue | €1.55m |
| Gross Profit | €2.97m |
| Other Expenses | €62.21m |
| Earnings | -€59.24m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 14, 2025
| Earnings per share (EPS) | -1.58 |
| Gross Margin | 65.67% |
| Net Profit Margin | -1,310.24% |
| Debt/Equity Ratio | 16.8% |
How did NYXH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/19 02:15 |
| End of Day Share Price | 2025/04/17 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nyxoah S.A. is covered by 10 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Rescott | Baird |
| Michael Polark | Baird |
| Ross Osborn | Cantor Fitzgerald & Co. |